ISER

ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research

Retrieved on: 
Monday, February 13, 2023
ONL, Fas receptor, European Association for Vision and Eye Research, Gold Coast Convention and Exhibition Centre, Safety, AMD, Patient, GA, International Society, Therapy, OAG, Convention center, ISER, ANN, Fas, Retina, Geographic atrophy, Pharmaceutical industry, Tobacco

ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver an oral presentation reviewing the scientific rationale for targeting the Fas receptor and the design of a Phase 1b study to evaluate the safety of ONL1204 ophthalmic solution for the treatment of patients with progressing open-angle glaucoma (OAG) at the upcoming XXVth Biennial Meeting of the International Society for Eye Research (ISER).

Key Points: 
  • ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver an oral presentation reviewing the scientific rationale for targeting the Fas receptor and the design of a Phase 1b study to evaluate the safety of ONL1204 ophthalmic solution for the treatment of patients with progressing open-angle glaucoma (OAG) at the upcoming XXVth Biennial Meeting of the International Society for Eye Research (ISER).
  • The ISER Meeting will take place February 19-23, 2023, at the Gold Coast Convention and Exhibition Centre in Broadbeach, Queensland, Australia.
  • Details of the presentation are as follows:
    1:00 p.m. Australian Eastern Standard Time on Tuesday, February 21, 2023
    As previously announced, ONL will also share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in an oral presentation at the ISER Meeting.
  • Details of that presentation are as follows:

ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research

Retrieved on: 
Thursday, January 26, 2023
ANN, Treatment, Geographic atrophy, Retina, European Association for Vision and Eye Research, International Society, Convention center, Gold Coast Convention and Exhibition Centre, GA, AMD, Patient, Geography, Macular Society, ISER, Therapy, Pharmaceutical industry

ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) at the upcoming 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research (ISER).

Key Points: 
  • ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) at the upcoming 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research (ISER).
  • The Macular Society Meeting is scheduled for February 15-18, 2023, at the Fontainebleau in Miami, Florida, while the ISER Meeting will take place February 19-23, 2023, at the Gold Coast Convention and Exhibition Centre in Broadbeach, Queensland, Australia.
  • Details of the Macular Society Meeting presentation are as follows:
    Fas Inhibition with ONL1204 for the Treatment of Geographic Atrophy: First-Time Interim Results from a Phase 1 Open-Label Dose Escalation Study
    2:34 p.m. Eastern Standard Time on Friday, February 17, 2023
    Details of the ISER Meeting presentation are as follows:

Alfa Romeo F1 Team ORLEN Selects Zadara as Official Cloud Supplier to Power a Second Season

Retrieved on: 
Wednesday, March 2, 2022
Data Management, Sports, Technology, Software, Motor Sports, Networks, Internet, Cloud, Midnight, ZCP, ISCSI Extensions for RDMA, ISER, Element, SLA, Solution, Alfa Romeo in Formula One, Multimedia, NPS, CEO, CET, VMware, Technology, Partnership, C42, RDMA, Sauber Motorsport, Formula, Video game console, Computer data storage, Zadara, F1

Zadara , a recognized leader in edge cloud services, and Sauber Motorsport , which manages and operates the Alfa Romeo F1 Team ORLEN entry in the Formula One world championship, today announced their continued partnership for a second season, with Zadara serving as Official Cloud Supplier.

Key Points: 
  • Zadara , a recognized leader in edge cloud services, and Sauber Motorsport , which manages and operates the Alfa Romeo F1 Team ORLEN entry in the Formula One world championship, today announced their continued partnership for a second season, with Zadara serving as Official Cloud Supplier.
  • View the full release here: https://www.businesswire.com/news/home/20220302005344/en/
    The new Zadara-sponsored Alfa Romeo F1 Team ORLEN car, the C42, was revealed on February 27.
  • Zadaras cloud services dramatically streamline our cloud infrastructure, while enhancing performance, improving latency and putting real-time race data at our fingertips, said Jan Monchaux, technical director for Alfa Romeo F1 Team ORLEN.
  • We are ecstatic to continue our support of the Alfa Romeo F1 Team ORLEN as they enter a new era.